Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)

NCT07447050 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT07447050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07447050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Recruiting
Start date
December 23, 2025
Completion date
December 31, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gastric (stomach) cancer, genitourinary cancer, gynecologic cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, sarcoma